A fascinating Q&A on the ethical and philosophical considerations in psychedelic science and explanations of the psychedelic experience.   Prof David Nutt David is a leading Neuroscientist and drug policy reform advocate. Formerly the Chief Drug Advisor to the UK government he is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the  …

In this webinar from the Student Psychedelic Conference, we hear from two groups doing amazing harm reduction work!   PsyCare Amanda Guzinska started working with PsyCare since 2013 having discovered them at a festival a couple of years prior while helping a friend through a difficult experience. Among her friends or even strangers in need,  …

A personal Q&A from two patients of psychedelic therapy:   Psilocybin for depression – Michael Bourne Michael Bourne is a 57-year-old website designer from the North East of England, who tried several unsuccessful depression treatments, including talking therapy and prescription medications, before turning to psilocybin clinical trials. Michael took part in research into psilocybin treatment  …

What Is Ayahuasca? The word ayahuasca is derived from the phrase “vine of the dead”, or “vine of the soul” in Quechuan languages – succinctly capturing its mystical and spiritual role in South American cultures. Ayahuasca is a psychedelic plant brew composed of two primary ingredients: 1) Banisteriopsis caapi and 2) Psychotria viridis. N,N-dimethyltryptamine (DMT),  …

In this webinar, two of the world’s leading psychedelic research experts; Dr Ben Sessa and Dr Meg Spriggs, answer questions on the therapeutic applications of MDMA and psilocybin!   Who is Dr Ben Sessa? Dr Ben Sessa is a consultant child and adolescent psychiatrist who has worked with young people and adults in the field  …

Psychedelic drugs in the Netherlands In the Netherlands, it’s not difficult to find a shop selling psychedelic drugs – magic truffles, cacti, 5-Meo-DMT, iboga, and the like are all widely available at ‘smart shops’. Retreat centers are also accessible within the country, where individuals can pay to trip in a safe environment, and undergo therapy  …

What does the future of psychedelics look like? In this Drug Science webinar, Sarah Hashkes, breaks down the key factors which will influence the future of psychedelics.   Why do psychedelics have so much potential and what does it have to do with ‘predictive coding’? “Predictive coding” refers to the brain function theory where the  …

In this Drug Science webinar, we learn how ayahuasca may be helpful in the treatment of addiction, trauma, and anger issues from addiction recovery coach Mark Drax, who describes the efficacy of ayahuasca to treat sex addiction. From the age of 3, Mark Drax’ childhood was riddled with physical abuse both in his home and  …

There is no defined road to legalising psychedelics, but there are many options available. Ismail Lourido Ali, of MAPS, discusses the important nuances in this Drug Science webinar on expanding access to psychedelics. Due to the recent progress of medical cannabis legalisation, many expect psychedelics to follow a similar path of medical legalisation, followed by  …

Could psilocybin be used for the treatment of OCD? Psilocybin is currently being researched as a treatment for OCD by Drug Science founder, Prof David Nutt, at the Centre for Psychedelic Research. In this Drug Science webinar, Dr Nick Sireau provides an overview of OCD and the new research being launched into psilocybin as a  …

In this Drug Science webinar, expert Neuropsychopharmacologist Professor David Nutt explains how psychedelic drugs such as psilocybin, LSD, DMT, and ayahuasca work in the human brain, and the applications for the treatment of mental health conditions such as depression, anxiety, and addiction. Prof Nutt outlines the history of psychedelic research, starting in the early 20th  …

The use of therapy assisted by psychedelics like psilocybin looks set to change the face of mental health care. But evidence from clinical trials suggests that it also changes patients in ways quite different to those seen following traditional treatment. In this Drug Science webinar, part of the inaugural Student Psychedelic Conference, Eddie Jacobs introduces  …

In this webinar, Dr Meg Spriggs explains the potential of psilocybin to treat anorexia nervosa, and offers valuable insights from the clinical trial investigating this application at the Centre for Psychedelic Research. Eating disorders are a complex mental health issue with few effective pharmaceutical treatments available. Meg provides an introductory background to some of the  …

In this webinar, Dr Ben Sessa explains how MDMA therapy could treat alcohol use disorder (alcoholism), based on results from his recent safety and tolerability study. He gives background into the psychological trauma which often causes addiction and alcohol use disorder, and how modern psychiatry struggles to treat these conditions at the root cause. He  …

As clinical trials reveal more evidence for the therapeutic potential of psychedelic drugs such as psilocybin, DMT, and even entheogens like MDMA, many psychedelic companies have sprung up to develop psychedelic drugs for specific applications. With promising results in the treatment of mental health conditions such as depression, addiction, anxiety, and more, investment interest in  …

Clinical trials are currently investigating psilocybin therapy, as a treatment for depression at research centres around the world. This webinar gives valuable insight into the benefits of psilocybin treatment, from the perspective of a patient who suffered from depression for most of his adult life. Michael Bourne is a 57-year-old website designer from the North  …